Lisinopril Dihydrate: ACE Inhibitor for Hypertension Research

Overview of Lisinopril Dihydrate and Its Research Principle

Lisinopril dihydrate is the dihydrate form of lisinopril, a benchmark long-acting angiotensin converting enzyme (ACE) inhibitor. As a lysine analogue of MK 421, this compound exerts its effect by potently inhibiting ACE activity (IC₅₀ = 4.7 nM), thereby preventing the conversion of angiotensin I to angiotensin II. The downstream result is a decrease in plasma angiotensin II and aldosterone levels, coupled with a compensatory rise in plasma renin, culminating in significant vasodilation and reduced fluid retention. These mechanisms underpin its broad application in hypertension research, heart failure models, acute myocardial infarction studies, and diabetic nephropathy.

Its molecular formula (C₂₁H₃₅N₃O₇), high purity (98%, QC-verified), and excellent aqueous solubility (≥2.46 mg/mL with gentle warming and ultrasonication) make it highly suitable for both in vitro and in vivo applications. Importantly, Lisinopril dihydrate is insoluble in ethanol, guiding solvent selection during experimental planning. APExBIO, a trusted supplier of research-grade compounds, ensures consistent quality, facilitating reproducible results across laboratories.

Step-by-Step Experimental Workflows with Lisinopril Dihydrate

1. Solubilization and Stock Preparation

• Weighing: Calculate the required amount based on a molecular weight of 441.52 g/mol. Use an analytical balance for precision.
• Solubilization: Dissolve Lisinopril dihydrate in sterile water to achieve concentrations ≥2.46 mg/mL. Gentle warming (up to 37°C) and ultrasonication facilitate rapid dissolution.
• Filtration: Sterile-filter (0.22 μm) for cell culture applications to prevent contamination.
• Aliquot and Storage: Divide into single-use aliquots. Store solids desiccated at room temperature; avoid long-term storage of aqueous solutions to maintain potency.

2. In Vitro Cellular Assays

• ACE Activity Assays: Preincubate cells or membrane preparations with Lisinopril dihydrate for 15–30 min before substrate addition. Use substrate concentrations near K_m for optimal sensitivity.
• Renin-Angiotensin System Pathway Analysis: Quantify angiotensin II, aldosterone, and renin levels using ELISA or LC-MS/MS post-treatment, as per established protocols (see this applied workflow).
• Viability and Off-Target Screening: Confirm specificity by including controls (vehicle, non-ACE peptidase inhibitors, or negative cell lines).

3. In Vivo Modeling

• Dose Selection: Reference published studies for starting doses (typically 1–20 mg/kg/day in rodent models). Titrate based on desired plasma ACE inhibition.
• Administration: Deliver via oral gavage, drinking water, or intraperitoneal injection. Monitor solubility and stability in chosen vehicle.
• Model Systems: Lisinopril dihydrate is established in hypertension (e.g., spontaneously hypertensive rats), heart failure, diabetic nephropathy, and myocardial infarction models.
• Sampling and Endpoints: Collect plasma/tissue samples at standardized intervals for biochemical and histological analysis.

4. Data Analysis and Reproducibility

• IC₅₀ Calculations: Utilize nonlinear regression for ACE inhibition curves; expect potent activity in the low-nanomolar range.
• Comparative Controls: Benchmark against other ACE inhibitors to validate selectivity and efficacy (see Tieku & Hooper, 1992).

Advanced Applications and Comparative Advantages

1. Mechanistic Dissection of the Renin-Angiotensin System

Lisinopril dihydrate is indispensable for dissecting the renin-angiotensin system pathway. Its high molecular specificity ensures selective inhibition of ACE without significant off-target effects on related zinc aminopeptidases, as demonstrated in comparative studies (Tieku & Hooper, 1992). Unlike some sulfhydryl ACE inhibitors, Lisinopril dihydrate does not inhibit aminopeptidase A or N, minimizing confounding effects in signaling studies—a key advantage for mechanistic research.

2. Translational Cardiovascular and Renal Research

Its robust performance in hypertension research, heart failure models, and diabetic nephropathy is underpinned by reproducible pharmacokinetics and batch-to-batch consistency. High aqueous solubility supports precise dosing in both cell-based and animal studies. The product’s Certificate of Analysis (COA) confirms ≥98% purity by mass spectrometry and NMR, ensuring reliable data for regulatory or translational applications.

3. Complementary and Contrasting Literature

• Lisinopril Dihydrate: ACE Inhibitor for Hypertension Research complements this article by offering a detailed protocol for renin-angiotensin system modulation in cardiovascular and renal disease models, reinforcing the importance of APExBIO’s formulation for reproducibility.
• Lisinopril Dihydrate: Applied ACE Inhibitor for Hypertension Research extends these insights with stepwise workflows and troubleshooting strategies, highlighting the compound’s versatility for both bench and translational studies.
• Lisinopril Dihydrate: Molecular Insights into ACE Inhibition contrasts by providing a systems-biology perspective, integrating omics and computational modeling to expand on Lisinopril dihydrate's research potential.

4. Answering Key Researcher Questions

What is lisinopril made from? Lisinopril is a synthetic lysine derivative of MK 421, designed to maximize ACE selectivity and oral bioavailability. Its dihydrate form, as provided by APExBIO, is optimized for laboratory use with validated purity and solubility profiles.

Troubleshooting and Optimization Tips

• Poor Solubility: If undissolved, gently warm the solution (≤37°C) and apply ultrasonication. Avoid organic solvents such as ethanol due to poor solubility.
• Batch Variability: Use APExBIO’s COA-verified lots to ensure consistent performance. Retain batch and QC records for reproducibility.
• Solution Stability: Prepare fresh working solutions immediately before use. Store solids desiccated at room temperature; discard solutions after 24 hours or if cloudiness/precipitation appears.
• Off-Target Effects: Incorporate negative controls and, if necessary, compare with sulfhydryl ACE inhibitors to rule out non-specific peptidase inhibition (see Tieku & Hooper, 1992 for specificity data).
• Assay Sensitivity: Optimize substrate concentrations and incubation times. For in vivo studies, confirm plasma compound levels via LC-MS/MS.

Future Outlook: Expanding the Impact of Lisinopril Dihydrate

Lisinopril dihydrate will continue to play a central role in unraveling the blood pressure regulation pathway and the broader renin-angiotensin system. Its high specificity, validated by comparative enzyme inhibition studies, supports its application in precision medicine and next-generation cardiovascular and renal disease models. Recent systems-biology approaches (see Molecular Insights into ACE Inhibition) point to expanded uses in omics-driven biomarker discovery and network pharmacology.

As bench-to-bedside research intensifies, APExBIO’s quality-assured Lisinopril dihydrate is poised to underpin breakthroughs in hypertension research, heart failure therapeutics, and diabetic nephropathy modeling. Researchers are encouraged to leverage protocol enhancements, troubleshooting strategies, and comparative literature to maximize experimental rigor and translational value.